Thyroid Cancer Stage II (Papillary/Follicular, age ≥55 years)

What Stage II (Papillary/Follicular, age ≥55 years) Means

Tumors >4 cm confined to thyroid (T3) OR any tumor with lateral lymph node metastases (N1b), no distant mets. Age ≥55 required for Stage II distinction.

Treatment Approach for Stage II (Papillary/Follicular, age ≥55 years)

Total thyroidectomy with lymph node dissection (central ± lateral if N1b); RAI ablation for T3, N1b, or both. TSH suppression moderate (target 0.1–0.5 mIU/L). More intensive surveillance (ultrasound, serum thyroglobulin every 6 months for 5 years).

Survival Rates and Prognosis

The 5-year survival rate for thyroid cancer at Stage II (Papillary/Follicular, age ≥55 years) is approximately 10-year survival 80–90%; extrathyroidal extension worsens outcomes.. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.

Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.

How Other Stages Compare

Stage	5-Year Survival	Treatment
Stage I (Papillary/Follicular, age <55 years)	10-year survival >95%; recurrence-free survival 80–90% with multimodal therapy (surgery + RAI if indicated).	Near-total or total thyroidectomy; radioactive iodine ablation if…
Stage I (Papillary/Follicular, age ≥55 years)	10-year survival 90–95%; lower than age <55 due to comorbidities, competing mortality.	Near-total or total thyroidectomy ± RAI (individualize based on tumor…
Stage III (Papillary/Follicular, age ≥55 years)	10-year survival 50–70%; depends on extent of invasion, resectability, nodal involvement.	Total thyroidectomy with en bloc resection of invaded structures (larynx,…
Stage IVA (Papillary/Follicular, age ≥55 years)	10-year survival 35–50%; prognosis worsens with distant spread.	Resection of primary + lymph node dissection if feasible. RAI ablation. EBRT…
Stage IVB (Papillary/Follicular)	10-year survival 10–40%; papillary with pulmonary mets more indolent (median OS >10 years); anaplastic with mets median OS <6 months.	RAI ablation if disease is RAI-avid (repeat 131-I therapy every 3–6…
Stage I–IV Medullary Thyroid Cancer (MTC)	Stage I: 10-year survival ~90%; Stage II: 70%; Stage III: 50%; Stage IV: 10–30%. Calcitonin doubling time (marker of disease progression) predicts survival.	Total thyroidectomy + central neck lymph node dissection…
Stage I–IV Anaplastic Thyroid Cancer (ATC)	Median overall survival untreated: 3–6 months; with aggressive multimodal therapy: 12–24 months in select patients. 5-year survival <5%.	Surgical resection if completely resectable (total thyroidectomy, lymph node…